The Latest Breaking News from Vertex

Whether you’re a soldier or a civvie, these timepieces are built for any situation

The FDA could approve Crispr Therapeutics' gene-edited sickle cell treatment as early as December. In response, CRSP stock surged Friday.

Vertex enters into a partnership to develop novel small molecules. Shares have gained 15% this year.

Medical stocks are holding up amid economic and market uncertainty.

After years of robust growth, the biotech industry has struggled since last year due to several headwinds, including regulatory concerns, inflation, and the Fed’s aggressive rate hikes, which have sucked out speculative capital. Despite currently being one of the poorly-rated industries, investors could consider buying top-biotech stocks Gilead (GILD), Vertex…

Vertex Pharmaceuticals is forming a base and back above its 50-day moving average. VRTX stock ranks third out of 792 biotechs.

Vertex Pharmaceuticals' fourth-quarter sales divided analysts Wednesday as VRTX stock toppled on a lack of near-term catalysts.

The Dow Jones fell 100 points Monday, with the Federal Reserve's policy meeting set for this week. Tesla stock was upgraded to buy.

The Dow Jones Industrial Average reversed higher Friday after key inflation data. Intel stock plunged over 10% on an earnings miss.